Clindamycin is not adequate for empiric therapy for Staphylococcal infections due to increased resistance. Given its association with C difficile colitis, its use should be limited to severe group A Strep sepsis.
It has an adjunctive antitoxin effect also, where it decreases ribosomal toxin production, and can lead to faster clinical improvement for streptococcal infections, like non-purulent cellulitis, necrotizing infections, and streptococcal toxic shock.
Gram positive
Gram negatives
Anaerobes
Other
Does not cover